NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 207 filers reported holding NEKTAR THERAPEUTICS in Q1 2017. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $9,566 | -68.6% | 13,610 | 0.0% | 0.00% | -100.0% |
| Q4 2022 | $30,486 | -29.1% | 13,610 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $43,000 | -15.7% | 13,610 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $51,000 | -94.3% | 13,610 | -72.5% | 0.00% | -93.8% |
| Q3 2021 | $890,000 | +4.6% | 49,581 | 0.0% | 0.03% | +3.2% |
| Q2 2021 | $851,000 | -14.2% | 49,581 | 0.0% | 0.03% | -18.4% |
| Q1 2021 | $992,000 | +17.7% | 49,581 | 0.0% | 0.04% | -2.6% |
| Q4 2020 | $843,000 | +0.4% | 49,581 | -2.1% | 0.04% | +2.6% |
| Q3 2020 | $840,000 | -29.6% | 50,647 | -1.6% | 0.04% | -33.3% |
| Q2 2020 | $1,193,000 | +35.0% | 51,491 | +4.0% | 0.06% | +14.0% |
| Q1 2020 | $884,000 | -17.2% | 49,500 | 0.0% | 0.05% | +6.4% |
| Q4 2019 | $1,068,000 | +1807.1% | 49,500 | +1516.1% | 0.05% | +1466.7% |
| Q3 2019 | $56,000 | -48.6% | 3,063 | 0.0% | 0.00% | -40.0% |
| Q2 2019 | $109,000 | +5.8% | 3,063 | 0.0% | 0.01% | 0.0% |
| Q1 2019 | $103,000 | +2.0% | 3,063 | 0.0% | 0.01% | -16.7% |
| Q4 2018 | $101,000 | -46.0% | 3,063 | 0.0% | 0.01% | -33.3% |
| Q3 2018 | $187,000 | +24.7% | 3,063 | 0.0% | 0.01% | +28.6% |
| Q2 2018 | $150,000 | -91.2% | 3,063 | -81.0% | 0.01% | -91.5% |
| Q1 2018 | $1,713,000 | +126.0% | 16,122 | +27.0% | 0.08% | +134.3% |
| Q4 2017 | $758,000 | +177.7% | 12,690 | -2.5% | 0.04% | +169.2% |
| Q3 2017 | $273,000 | +7.5% | 13,011 | 0.0% | 0.01% | +8.3% |
| Q2 2017 | $254,000 | -10.6% | 13,011 | +7.7% | 0.01% | -14.3% |
| Q1 2017 | $284,000 | +91.9% | 12,082 | 0.0% | 0.01% | +100.0% |
| Q4 2016 | $148,000 | -22.9% | 12,082 | +8.0% | 0.01% | -30.0% |
| Q3 2016 | $192,000 | +33.3% | 11,182 | +10.2% | 0.01% | +11.1% |
| Q2 2016 | $144,000 | +2.9% | 10,150 | 0.0% | 0.01% | 0.0% |
| Q1 2016 | $140,000 | -18.1% | 10,150 | 0.0% | 0.01% | -25.0% |
| Q4 2015 | $171,000 | +54.1% | 10,150 | 0.0% | 0.01% | +50.0% |
| Q3 2015 | $111,000 | -12.6% | 10,150 | 0.0% | 0.01% | 0.0% |
| Q2 2015 | $127,000 | +1.6% | 10,150 | -10.8% | 0.01% | 0.0% |
| Q1 2015 | $125,000 | -29.0% | 11,378 | 0.0% | 0.01% | -33.3% |
| Q4 2014 | $176,000 | +28.5% | 11,378 | 0.0% | 0.01% | +20.0% |
| Q3 2014 | $137,000 | -6.2% | 11,378 | 0.0% | 0.01% | -9.1% |
| Q2 2014 | $146,000 | +11.5% | 11,378 | +5.1% | 0.01% | +10.0% |
| Q1 2014 | $131,000 | – | 10,830 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |